Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob M Rowe

Showing results (141-150 of 275) with videos related to

Pageof 28
Sort By:
Cancer|June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerantMaya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
American Journal of Hematology|September 30, 2011
A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preservedEldad J Dann, Zeev Blumenfeld, Rachel Bar-Shalom, et al.
Blood|October 24, 2002
Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipientsDana G Wolf, Nell S Lurain, Tsila Zuckerman, et al.
Leukemia Research|June 19, 2004
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Martin S Tallman, Isadore Brodsky, et al.
Leukemia Research|January 18, 2006
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe, Kevin Rader, Martin S Tallman, et al.
Blood|May 21, 2013
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemiaPieter Van Vlierberghe, Alberto Ambesi-Impiombato, Kim De Keersmaecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemiasDejan Juric, Norman J Lacayo, Meghan C Ramsey, et al.
Blood|October 5, 2006
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcomeEldad J Dann, Rachel Bar-Shalom, Ada Tamir, et al.
Blood|June 10, 2011
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidJae H Park, Baozhen Qiao, Katherine S Panageas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2014
Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remissionJennifer L Holter Chakrabarty, Morel Rubinger, Jennifer Le-Rademacher, et al.
Pageof 28

Showing results (141-150 of 275) with videos related to

Sort By:
Pageof 28
Cancer|June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerantMaya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
American Journal of Hematology|September 30, 2011
A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preservedEldad J Dann, Zeev Blumenfeld, Rachel Bar-Shalom, et al.
Blood|October 24, 2002
Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipientsDana G Wolf, Nell S Lurain, Tsila Zuckerman, et al.
Leukemia Research|June 19, 2004
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Martin S Tallman, Isadore Brodsky, et al.
Leukemia Research|January 18, 2006
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe, Kevin Rader, Martin S Tallman, et al.
Blood|May 21, 2013
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemiaPieter Van Vlierberghe, Alberto Ambesi-Impiombato, Kim De Keersmaecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemiasDejan Juric, Norman J Lacayo, Meghan C Ramsey, et al.
Blood|October 5, 2006
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcomeEldad J Dann, Rachel Bar-Shalom, Ada Tamir, et al.
Blood|June 10, 2011
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidJae H Park, Baozhen Qiao, Katherine S Panageas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2014
Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remissionJennifer L Holter Chakrabarty, Morel Rubinger, Jennifer Le-Rademacher, et al.
Pageof 28